Rabbit Recombinant Monoclonal UBA5 antibody - conjugated to Alexa Fluor® 568.
pH: 7.4
Preservative: 0.02% Sodium azide
Constituents: 68% PBS, 30% Glycerol (glycerin, glycerine), 1% BSA
| Application | Reactivity | Dilution info | Notes |
|---|---|---|---|
Application Target Binding Affinity | Reactivity Expected | Dilution info - | Notes - |
Application Antibody Labelling | Reactivity Expected | Dilution info - | Notes - |
Select an associated product type
E1-like enzyme which specifically catalyzes the first step in ufmylation (PubMed:15071506, PubMed:18442052, PubMed:20368332, PubMed:25219498, PubMed:26929408, PubMed:27545674, PubMed:27545681, PubMed:27653677, PubMed:30412706, PubMed:30626644, PubMed:34588452). Activates UFM1 by first adenylating its C-terminal glycine residue with ATP, and thereafter linking this residue to the side chain of a cysteine residue in E1, yielding a UFM1-E1 thioester and free AMP (PubMed:20368332, PubMed:26929408, PubMed:27653677, PubMed:30412706). Activates UFM1 via a trans-binding mechanism, in which UFM1 interacts with distinct sites in both subunits of the UBA5 homodimer (PubMed:27653677). Trans-binding also promotes stabilization of the UBA5 homodimer, and enhances ATP-binding (PubMed:29295865). Transfer of UFM1 from UBA5 to the E2-like enzyme UFC1 also takes place using a trans mechanism (PubMed:27653677, PubMed:34588452). Ufmylation plays a key role in various processes, such as ribosome recycling, response to DNA damage, interferon response or reticulophagy (also called ER-phagy) (PubMed:30412706, PubMed:32160526, PubMed:35394863). Ufmylation is essential for erythroid differentiation of both megakaryocytes and erythrocytes (By similarity).
UBE1DC1, UBA5, Ubiquitin-like modifier-activating enzyme 5, Ubiquitin-activating enzyme 5, ThiFP1, UFM1-activating enzyme, Ubiquitin-activating enzyme E1 domain-containing protein 1
Rabbit Recombinant Monoclonal UBA5 antibody - conjugated to Alexa Fluor® 568.
pH: 7.4
Preservative: 0.02% Sodium azide
Constituents: 68% PBS, 30% Glycerol (glycerin, glycerine), 1% BSA
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling.
For suitable applications and species reactivity, please refer to the unconjugated version of this clone. This conjugated antibody is eligible for the Abcam trial program.
UBA5 also known as Ubiquitin-like modifier-activating enzyme 5 is an E1 enzyme that plays a mechanical role in activating ubiquitin-fold modifier 1 (UFM1) for protein modification. It has a molecular mass of about 44 kDa and performs its function in the nucleus and cytoplasm within human cells. The expression of UBA5 is not limited to specific tissues; instead it shows widespread expression across many tissues supporting an important role in various cellular processes.
UBA5 is implicated in the UFM1 conjugation system. This process modifies specific proteins and affects protein stability interaction and degradation. UBA5 operates in complex with UFC1 an E2 enzyme enabling the transfer of UFM1 to target proteins. Its activity is essential for maintaining cellular homeostasis particularly in the endoplasmic reticulum stress response through protein modification and regulation tasks.
The UBA5-UFM1 axis integrates into the cellular stress response pathway and the endoplasmic reticulum-associated degradation (ERAD) pathway. Through these pathways UBA5 collaborates with proteins like UFL1 further connecting these pathways by tagging proteins with UFM1 to mark them for degradation or functional modification. The coordination between UBA5 and UFL1 supports efficient protein quality control and maintains cellular equilibrium under stress conditions.
The dysfunction or altered expression of UBA5 associates with neurodevelopmental disorders and some cancers. Changes in UBA5 activity can lead to imbalances in protein homeostasis contributing to pathogenic mechanisms in neurodevelopmental disorders where other proteins like EIF4A1 also play a role. In cancer alterations in UBA5 expression may influence tumor progression as seen in cases where UBA5 levels affect pathways that involve p53 an important tumor suppressor protein.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com